Figure 2.

Clinical course and remission in the patient with Ph+ALL treated with bortezomib. The graph shows persistence of BCR-ABL-positive disease despite correction of white counts in the initial phase of the disease, when the patient was treated with leukopheresis, followed by induction chemotherapy and TKI (Imatinib). Bortezomib was added at approximately 6 months following diagnosis. Bortezomib and rituxan are maintained at alternate months, while dasatinib is given orally every day. Her BCR-ABL expression levels, by molecular analysis (RT-PCR for p210 transcripts), turned negative following this combination regimen. The data is truncated at 35 months. The patient maintains a similar status at 48 months at last follow-up.